Description: Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orions net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orions A and B shares are listed on NASDAQ OMX Helsinki.
Home Page: www.orion.fi
Orionintie 1A
Espoo,
02200
Finland
Phone:
358 10 4261
Officers
| Name | Title |
|---|---|
| Mr. Timo Lappalainen | Advisor |
| Dr. Liisa Hurme | Pres, CEO & Chairman of Exec. Management Board |
| Mr. Jari Karlson M.Sc., M.Sc. (Econ.) | CFO, Sr. VP of Animal Health & Member of the Exec. Management Board |
| Mr. Olli Huotari Ll.M. | Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board |
| Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) | Sr. VP of Commercial Operations & Member of the Exe. Mgmt. Board |
| Ms. Virve Laitinen M.Sc. (Tech.), MBA | Sr. VP of Specialty Products & Member of Exec. Management Board |
| Prof. Outi Vaarala M.D., Ph.D. | Sr. VP for R&D and Member of Exec. Management Board |
| Mr. Juhani Kankaanpaa | Sr. VP of Global Operations & Member of Exec. Management Board |
| Mr. Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations & Financial Communications Officer |
| Ms. Terhi Ormio | VP of Communications |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 19.7628 |
|---|---|
| Trailing PE: | 21.0902 |
| Price-to-Book MRQ: | 5.505 |
| Price-to-Sales TTM: | 7.535 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3527 |